A catecholamine-independent pathway controlling adaptive adipocyte lipolysis.

Summary

Using a brain-evoked fat-depletion mouse model, the authors identify a powerful, catecholamine-independent lipolytic program that rapidly catabolizes even stable adipose depots under concurrent hypoglycemia and hypoinsulinemia. This pathway requires ATGL and involves downregulating cell-autonomous lipolytic brakes such as G0s2, and is recapitulated in tumor-associated cachexia.

Key Findings

• Brain-evoked adipose catabolism depleted all fat depots, including constitutive bone marrow adipose tissue, without changes in food intake.
• Lipolysis required adipose triglyceride lipase (ATGL) and was independent of local nerves, sympathetic nervous system, and catecholamines.
• Concurrent hypoglycemia and hypoinsulinemia activated a potent lipolytic state by downregulating lipolysis inhibitors such as G0s2.
• The catecholamine-independent program delipidated classical depots and was reproduced in tumor-associated cachexia mice.

Clinical Implications

Targeting catecholamine-independent lipolysis regulators (e.g., ATGL activation or G0S2 modulation) could open new strategies to treat cancer cachexia and refractory adiposity states, but careful translational work is needed to avoid worsening glycemic instability in diabetes.

Limitations

• Preclinical murine model; no human interventional validation
• Potential off-target systemic effects of inducing hypoglycemia/hypoinsulinemia not addressed clinically

Future Directions

Define the central circuits triggering this neurosystemic program, test pharmacologic modulation of ATGL/G0S2 in cachexia, and validate biomarkers and safety in early human studies.